Published in BMJ on November 11, 2008
Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry | NCT02778646
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int (2014) 2.12
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype. Circulation (2016) 1.47
Hypercholesterolemia among apparently healthy university students. Oman Med J (2012) 1.42
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther (2014) 1.15
Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One (2010) 1.14
Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc (2013) 1.08
Cascade Screening for Familial Hypercholesterolemia (FH). PLoS Curr (2011) 0.98
Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes Metab J (2015) 0.94
Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. Am Heart J (2014) 0.88
Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med (2014) 0.87
Familial hypercholesterolemia: present and future management. Curr Cardiol Rep (2011) 0.86
A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genet Med (2015) 0.84
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Malar J (2013) 0.84
No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with familial hypercholesterolemia compared to usual care: results of a randomised controlled trial. BMC Res Notes (2012) 0.83
Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol (2015) 0.83
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiol Ther (2015) 0.83
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res (2012) 0.82
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid (2012) 0.82
Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol (2010) 0.81
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet (2016) 0.81
Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study. Eur J Hum Genet (2012) 0.81
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis (2011) 0.80
Can multiple lifestyle behaviours be improved in people with familial hypercholesterolemia? Results of a parallel randomised controlled trial. PLoS One (2012) 0.80
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. Clin Cardiol (2017) 0.80
Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Wien Klin Wochenschr (2015) 0.79
The genetics of familial hypercholesterolemia and emerging therapies. Appl Clin Genet (2015) 0.79
Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet (2015) 0.78
Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia. BMC Med Genet (2010) 0.78
My Approach to the Patient With Familial Hypercholesterolemia. Mayo Clin Proc (2016) 0.78
A novel mutation (Cys308Phe) of the LDL receptor gene in families from the South-Eastern part of Poland. Mol Biol Rep (2011) 0.78
Exploring Gaps of Family History Documentation in EHR for Precision Medicine -A Case Study of Familial Hypercholesterolemia Ascertainment. AMIA Jt Summits Transl Sci Proc (2016) 0.77
Temporal trends in lipid screening and therapy among youth from 2002 to 2012. J Clin Lipidol (2015) 0.77
Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics. J Eval Clin Pract (2015) 0.77
Development of Human-Like Advanced Coronary Plaques in Low-Density Lipoprotein Receptor Knockout Pigs and Justification for Statin Treatment Before Formation of Atherosclerotic Plaques. J Am Heart Assoc (2016) 0.77
Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol (2015) 0.77
Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis (2014) 0.77
Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol (2014) 0.76
The genetics and screening of familial hypercholesterolaemia. J Biomed Sci (2016) 0.76
Clinical utility gene card for: hyperlipoproteinemia, TYPE II. Eur J Hum Genet (2013) 0.76
Genetics of Lipid and Lipoprotein Disorders and Traits. Curr Genet Med Rep (2016) 0.76
Identification of Medically Actionable Secondary Findings in the 1000 Genomes. PLoS One (2015) 0.76
Genetic testing of familial hypercholesterolemia in a real clinical setting. Wien Klin Wochenschr (2016) 0.76
Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs? Healthcare (Basel) (2015) 0.75
Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study. JRSM Cardiovasc Dis (2012) 0.75
New Approaches in Detection and Treatment of Familial Hypercholesterolemia. Curr Cardiol Rep (2015) 0.75
Statins and familial hypercholesterolaemia. BMJ (2009) 0.75
When less is more - efficacy with less toxicity at the ED50. Br J Clin Pharmacol (2017) 0.75
A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. Clin Biochem Rev (2012) 0.75
Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol (2016) 0.75
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Can Fam Physician (2016) 0.75
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol (2016) 0.75
Quality assessment of the genetic test for familial hypercholesterolemia in the Netherlands. Cholesterol (2013) 0.75
Familial hypercholesterolemia. Cardiol Clin (2015) 0.75
Familial hypercholesterolemia--screening to facilitate early prevention. Dtsch Arztebl Int (2014) 0.75
Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vasc Health Risk Manag (2017) 0.75
[Congenital disorders of lipoprotein metabolism]. Herz (2017) 0.75
Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys. Ann Intern Med (2017) 0.75
Unhealthy smokers: scopes for prophylactic intervention and clinical treatment. BMC Neurosci (2017) 0.75
The UCL low-density lipoprotein receptor gene variant database: pathogenicity update. J Med Genet (2016) 0.75
Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol (1991) 7.67
Lipid screening and cardiovascular health in childhood. Pediatrics (2008) 6.62
Are lipid-lowering guidelines evidence-based? Lancet (2007) 4.55
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis (1999) 3.33
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 2.97
Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation (2007) 2.15
Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol (2004) 1.70
The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med (2004) 1.46
Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol (2005) 1.20
Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis (2004) 0.97
Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ (2004) 0.94
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol (2005) 0.94
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol (2006) 5.39
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care (2007) 4.69
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol (2012) 3.66
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes (2008) 3.54
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
Corticosteroids and the risk of atrial fibrillation. Arch Intern Med (2006) 3.28
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
Genetic variant of the scavenger receptor BI in humans. N Engl J Med (2011) 2.69
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc (2013) 2.47
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (2002) 2.39
UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem (2003) 2.37
Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med (2009) 2.30
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol (2007) 2.26
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med (2007) 2.26
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Setting and registry characteristics affect the prevalence and nature of multimorbidity in the elderly. J Clin Epidemiol (2008) 2.20
Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17
Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res (2013) 2.15
Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation (2007) 2.15
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care (2010) 2.14
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 2.09
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
Improvement of risk prediction by genomic profiling: reclassification measures versus the area under the receiver operating characteristic curve. Am J Epidemiol (2010) 2.06
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J (2009) 2.06
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05
Eating fish and risk of type 2 diabetes: A population-based, prospective follow-up study. Diabetes Care (2009) 2.03
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02
Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. Proc Natl Acad Sci U S A (2011) 2.01
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes (2006) 1.97
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol (2009) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet (2009) 1.96
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet (2009) 1.95
Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc (2007) 1.91
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart (2010) 1.91
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J (2012) 1.91
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation (2008) 1.91
Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation (2003) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation (2002) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes (2007) 1.86
Heritability of blood pressure traits and the genetic contribution to blood pressure variance explained by four blood-pressure-related genes. J Hypertens (2007) 1.85
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J (2011) 1.84
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet (2004) 1.84
LPIN2 is associated with type 2 diabetes, glucose metabolism, and body composition. Diabetes (2007) 1.83
Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J (2008) 1.80